Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
The 7 major dystrophic epidermolysis bullosa markets reached a value of US$ 525.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,857.8 Million by 2034, exhibiting a growth rate (CAGR) of 12.2% during 2024-2034.
The Dystrophic Epidermolysis Bullosa market has been comprehensively analyzed in IMARC's new report titled "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast". Dystrophic epidermolysis bullosa refers to a rare genetic condition that causes the skin to blister or tear easily. The response could be to a minor injury or friction, such as rubbing or scratching or even from heat. The signs and symptoms of dystrophic epidermolysis bullosa generally differ among individuals. In mild cases, blistering may affect hands, feet, knees, and elbows, while in severe cases, widespread blistering occurs, which leads to scarring, vision loss, and other medical problems. The disease is diagnosed by identifying biallelic pathogenic variants (RDEB) or a heterozygous pathogenic variant (DDEB) in COL7A1 by molecular genetic testing. Currently, the available treatment focuses on managing symptoms and complications. Some of the common treatment available for dystrophic epidermolysis bullosa, include moisturizers to lessen friction and irritation, non-adhesive bandages and dressings to protect the wound, and medicines to ease the pain.
The rising incidences of rare genetic disorders coupled with the inflating demand for novel medications that can treat the conditions effectively are primarily driving the global dystrophic epidermolysis bullosa market. Besides this, the increasing patient willingness to pay for expensive treatments, such as gene therapy, cell-based therapy, molecular therapy, etc., is further augmenting the global market. Moreover, the emerging popularity of non-adhesive semiocclusive dressings, including soft silicone and foam dressings, for treating dystrophic epidermolysis bullosa since they absorb exudate and reduce pain and blister formation during dressing is also acting as another growth-inducing factor. In addition to this, numerous stakeholders are making significant investments in R&D activities to gain a clear understanding of the disease etiopathogenesis for developing new and cutting-edge therapy alternatives. This, in turn, is further creating a positive outlook for the market. Furthermore, the introduction of several treatment alternatives, such as stem cell transplantation and gene correction, is also bolstering the market growth. Additionally, the escalating need for more effective and personalized therapies with improved long-term side effect profiles is further expected to bolster the global dystrophic epidermolysis bullosa market in the coming years.
IMARC Group's new report "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast" provides an exhaustive analysis of the Dystrophic Epidermolysis Bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Dystrophic Epidermolysis Bullosa market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Dystrophic Epidermolysis Bullosa across the seven major markets. According to the report the United States has the largest patient pool for Dystrophic Epidermolysis Bullosa and also represents the largest market for Dystrophic Epidermolysis Bullosa treatment. Furthermore, the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dystrophic Epidermolysis Bullosa market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Dystrophic Epidermolysis Bullosa Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Dystrophic Epidermolysis Bullosa Market
Sales of Various Drugs Across the Dystrophic Epidermolysis Bullosa Market
Reimbursement Scenario in the Dystrophic Epidermolysis Bullosa Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Dystrophic Epidermolysis Bullosa marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Dystrophic Epidermolysis Bullosa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Dystrophic Epidermolysis Bullosa market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Dystrophic Epidermolysis Bullosa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Dystrophic Epidermolysis Bullosa market?
Epidemiology Insights
What is the size of the Dystrophic Epidermolysis Bullosa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Dystrophic Epidermolysis Bullosa across the seven major markets?
What are the key factors driving the epidemiological trend of Dystrophic Epidermolysis Bullosa?
What will be the growth rate of Dystrophic Epidermolysis Bullosa patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their market performance?
What are the key pipeline Dystrophic Epidermolysis Bullosa drugs and how are they expected to perform in the coming years?
How safe are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
How safe are the late-stage pipeline Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
What are the current treatment guidelines for Dystrophic Epidermolysis Bullosa drugs across the seven major markets?
Who are the key companies in the Dystrophic Epidermolysis Bullosa market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dystrophic Epidermolysis Bullosa market?
The Dystrophic Epidermolysis Bullosa market has been comprehensively analyzed in IMARC's new report titled "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast". Dystrophic epidermolysis bullosa refers to a rare genetic condition that causes the skin to blister or tear easily. The response could be to a minor injury or friction, such as rubbing or scratching or even from heat. The signs and symptoms of dystrophic epidermolysis bullosa generally differ among individuals. In mild cases, blistering may affect hands, feet, knees, and elbows, while in severe cases, widespread blistering occurs, which leads to scarring, vision loss, and other medical problems. The disease is diagnosed by identifying biallelic pathogenic variants (RDEB) or a heterozygous pathogenic variant (DDEB) in COL7A1 by molecular genetic testing. Currently, the available treatment focuses on managing symptoms and complications. Some of the common treatment available for dystrophic epidermolysis bullosa, include moisturizers to lessen friction and irritation, non-adhesive bandages and dressings to protect the wound, and medicines to ease the pain.
The rising incidences of rare genetic disorders coupled with the inflating demand for novel medications that can treat the conditions effectively are primarily driving the global dystrophic epidermolysis bullosa market. Besides this, the increasing patient willingness to pay for expensive treatments, such as gene therapy, cell-based therapy, molecular therapy, etc., is further augmenting the global market. Moreover, the emerging popularity of non-adhesive semiocclusive dressings, including soft silicone and foam dressings, for treating dystrophic epidermolysis bullosa since they absorb exudate and reduce pain and blister formation during dressing is also acting as another growth-inducing factor. In addition to this, numerous stakeholders are making significant investments in R&D activities to gain a clear understanding of the disease etiopathogenesis for developing new and cutting-edge therapy alternatives. This, in turn, is further creating a positive outlook for the market. Furthermore, the introduction of several treatment alternatives, such as stem cell transplantation and gene correction, is also bolstering the market growth. Additionally, the escalating need for more effective and personalized therapies with improved long-term side effect profiles is further expected to bolster the global dystrophic epidermolysis bullosa market in the coming years.
IMARC Group's new report "Dystrophic Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast" provides an exhaustive analysis of the Dystrophic Epidermolysis Bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Dystrophic Epidermolysis Bullosa market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Dystrophic Epidermolysis Bullosa across the seven major markets. According to the report the United States has the largest patient pool for Dystrophic Epidermolysis Bullosa and also represents the largest market for Dystrophic Epidermolysis Bullosa treatment. Furthermore, the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Dystrophic Epidermolysis Bullosa market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Dystrophic Epidermolysis Bullosa Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Dystrophic Epidermolysis Bullosa Market
Sales of Various Drugs Across the Dystrophic Epidermolysis Bullosa Market
Reimbursement Scenario in the Dystrophic Epidermolysis Bullosa Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Dystrophic Epidermolysis Bullosa marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Dystrophic Epidermolysis Bullosa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Dystrophic Epidermolysis Bullosa market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Dystrophic Epidermolysis Bullosa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Dystrophic Epidermolysis Bullosa market?
Epidemiology Insights
What is the size of the Dystrophic Epidermolysis Bullosa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Dystrophic Epidermolysis Bullosa across the seven major markets?
What are the key factors driving the epidemiological trend of Dystrophic Epidermolysis Bullosa?
What will be the growth rate of Dystrophic Epidermolysis Bullosa patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their market performance?
What are the key pipeline Dystrophic Epidermolysis Bullosa drugs and how are they expected to perform in the coming years?
How safe are the current marketed Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
How safe are the late-stage pipeline Dystrophic Epidermolysis Bullosa drugs and what are their efficacies?
What are the current treatment guidelines for Dystrophic Epidermolysis Bullosa drugs across the seven major markets?
Who are the key companies in the Dystrophic Epidermolysis Bullosa market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Dystrophic Epidermolysis Bullosa market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSTROPHIC EPIDERMOLYSIS BULLOSA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 DYSTROPHIC EPIDERMOLYSIS BULLOSA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSTROPHIC EPIDERMOLYSIS BULLOSA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 DYSTROPHIC EPIDERMOLYSIS BULLOSA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Dystrophic Epidermolysis Bullosa Guidelines, Management and Treatment
8.2 Dystrophic Epidermolysis Bullosa Treatment Algorithm
9 DYSTROPHIC EPIDERMOLYSIS BULLOSA - UNMET NEEDS
10 DYSTROPHIC EPIDERMOLYSIS BULLOSA - KEY ENDPOINTS OF TREATMENT
11 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKETED PRODUCTS
11.1 List of Dystrophic Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
12 DYSTROPHIC EPIDERMOLYSIS BULLOSA - PIPELINE DRUGS
12.1 List of Dystrophic Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 Dabocemagene autoficel - Fibrocell Science
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 EB-101 - Abeona Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PTR-01 - Phoenix Tissue Repair
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Timbetasin - RegeneRx Biopharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report
13 DYSTROPHIC EPIDERMOLYSIS BULLOSA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Dystrophic Epidermolysis Bullosa - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Dystrophic Epidermolysis Bullosa - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Dystrophic Epidermolysis Bullosa - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Dystrophic Epidermolysis Bullosa - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Dystrophic Epidermolysis Bullosa - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Dystrophic Epidermolysis Bullosa - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Dystrophic Epidermolysis Bullosa - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Dystrophic Epidermolysis Bullosa - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
15 DYSTROPHIC EPIDERMOLYSIS BULLOSA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 DYSTROPHIC EPIDERMOLYSIS BULLOSA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DYSTROPHIC EPIDERMOLYSIS BULLOSA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 DYSTROPHIC EPIDERMOLYSIS BULLOSA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DYSTROPHIC EPIDERMOLYSIS BULLOSA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 DYSTROPHIC EPIDERMOLYSIS BULLOSA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Dystrophic Epidermolysis Bullosa Guidelines, Management and Treatment
8.2 Dystrophic Epidermolysis Bullosa Treatment Algorithm
9 DYSTROPHIC EPIDERMOLYSIS BULLOSA - UNMET NEEDS
10 DYSTROPHIC EPIDERMOLYSIS BULLOSA - KEY ENDPOINTS OF TREATMENT
11 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKETED PRODUCTS
11.1 List of Dystrophic Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
12 DYSTROPHIC EPIDERMOLYSIS BULLOSA - PIPELINE DRUGS
12.1 List of Dystrophic Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 Dabocemagene autoficel - Fibrocell Science
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 EB-101 - Abeona Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PTR-01 - Phoenix Tissue Repair
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Timbetasin - RegeneRx Biopharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report
13 DYSTROPHIC EPIDERMOLYSIS BULLOSA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 DYSTROPHIC EPIDERMOLYSIS BULLOSA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Dystrophic Epidermolysis Bullosa - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Dystrophic Epidermolysis Bullosa - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Dystrophic Epidermolysis Bullosa - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Dystrophic Epidermolysis Bullosa - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Dystrophic Epidermolysis Bullosa - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Dystrophic Epidermolysis Bullosa - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Dystrophic Epidermolysis Bullosa - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Dystrophic Epidermolysis Bullosa - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
15 DYSTROPHIC EPIDERMOLYSIS BULLOSA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 DYSTROPHIC EPIDERMOLYSIS BULLOSA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
